A drug proven effective for treatment of adults and children with sickle cell anemia reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to an analysis led by St. Jude Children's Research Hospital. The report appears in the advance online edition of the journal Pediatrics. The study is the largest ever focusing on the economic impact of the drug hydroxyurea in children with the inherited blood disorder...
No comments:
Post a Comment